Some of the patients also received adenovirus vector-based vaccines, including ETBX-051 (Etubics/ImmunityBio), a brachyury vaccine that after subcutaneous administration expresses brachyury that is predicted to elicit a cytotoxic T lymphocyte (CTL)-mediated immune response against tumor cells expressing brachyury and ETBX-061, which, like ETBX-051, is an adenovirus vector-based vaccine that expresses the transmembrane mucin MUC1 (34) after subcutaneous delivery. The gene discussed is TBX1; the disease is neoplasm.